Article info
PDFClinical and epidemiological research
Extended report
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
- Correspondence to Professor Tsutomu Takeuchi, Division of Rheumatology, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan;tsutake{at}z5.keio.jp
Citation
Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
Publication history
- Accepted August 21, 2012
- First published September 14, 2012.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 May 2021).
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Supplementary Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/